1. Home
  2. RNAZ vs FRSX Comparison

RNAZ vs FRSX Comparison

Compare RNAZ & FRSX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RNAZ
  • FRSX
  • Stock Information
  • Founded
  • RNAZ 2016
  • FRSX N/A
  • Country
  • RNAZ United States
  • FRSX Israel
  • Employees
  • RNAZ N/A
  • FRSX N/A
  • Industry
  • RNAZ Biotechnology: Pharmaceutical Preparations
  • FRSX Computer Software: Prepackaged Software
  • Sector
  • RNAZ Health Care
  • FRSX Technology
  • Exchange
  • RNAZ Nasdaq
  • FRSX Nasdaq
  • Market Cap
  • RNAZ 6.1M
  • FRSX 7.3M
  • IPO Year
  • RNAZ 2021
  • FRSX 2017
  • Fundamental
  • Price
  • RNAZ $11.51
  • FRSX $0.36
  • Analyst Decision
  • RNAZ Strong Buy
  • FRSX
  • Analyst Count
  • RNAZ 1
  • FRSX 0
  • Target Price
  • RNAZ $280.00
  • FRSX N/A
  • AVG Volume (30 Days)
  • RNAZ 251.6K
  • FRSX 872.6K
  • Earning Date
  • RNAZ 08-22-2025
  • FRSX 08-19-2025
  • Dividend Yield
  • RNAZ N/A
  • FRSX N/A
  • EPS Growth
  • RNAZ N/A
  • FRSX N/A
  • EPS
  • RNAZ N/A
  • FRSX N/A
  • Revenue
  • RNAZ N/A
  • FRSX $436,000.00
  • Revenue This Year
  • RNAZ N/A
  • FRSX N/A
  • Revenue Next Year
  • RNAZ N/A
  • FRSX N/A
  • P/E Ratio
  • RNAZ N/A
  • FRSX N/A
  • Revenue Growth
  • RNAZ N/A
  • FRSX N/A
  • 52 Week Low
  • RNAZ $6.15
  • FRSX $0.34
  • 52 Week High
  • RNAZ $739.20
  • FRSX $2.63
  • Technical
  • Relative Strength Index (RSI)
  • RNAZ 56.95
  • FRSX 29.09
  • Support Level
  • RNAZ $10.16
  • FRSX $0.35
  • Resistance Level
  • RNAZ $12.10
  • FRSX $0.40
  • Average True Range (ATR)
  • RNAZ 1.40
  • FRSX 0.04
  • MACD
  • RNAZ -0.11
  • FRSX -0.00
  • Stochastic Oscillator
  • RNAZ 23.51
  • FRSX 10.67

About RNAZ TransCode Therapeutics Inc.

TransCode Therapeutics Inc is a biopharmaceutical company focused on developing and commercializing innovative drugs and diagnostics for treating and identifying cancer. TransCode recently commenced its first clinical trial. The Company's lead therapeutic candidate, TTX-MC138, comprises an oligonucleotide conjugated to an iron oxide nanoparticle designed to be administered by infusion to inhibit the ability of metastatic tumor cells to survive. The goal of the therapy, if approved, is to achieve durable disease regression and long-term patient survival.

About FRSX Foresight Autonomous Holdings Ltd.

Foresight Autonomous Holdings Ltd is a technology company engaged in the design, development and commercialization of vision systems for the automotive industry. The company develops both in-line-of-sight vision systems and beyond-line-of-sight cellular-based applications through its wholly-owned subsidiaries. Its systems are designed to improve driving safety by enabling accurate and reliable threat detection while ensuring the lowest rates of false alerts. Foresight is pursuing several markets and believes its modern systems will revolutionize automotive safety by providing an automotive-grade, cost-effective platform.

Share on Social Networks: